Related Experiment Video
Updated: Jul 9, 2025
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Outcomes Among Patients Hospitalized for COVID-19 Treated with Remdesivir in an Urban Center Pre-COVID-19 Vaccination
Debra Chew1, Stephanie Shiau2, Sree Sudharshan2
1Division of Infectious Diseases, Rutgers New Jersey Medical School, 185 South Orange Avenue, MSB I-689, Newark, NJ, 07101, USA. chewde@njms.rutgers.edu.
Insights
Remdesivir effectively treated COVID-19 in a predominantly minority population. Advanced age and comorbidities were linked to worse outcomes, highlighting the need for targeted treatment strategies for vulnerable groups.
Area of Science:
- Infectious Diseases
- Clinical Medicine
- Public Health
Background:
- Limited data exists on remdesivir treatment outcomes in minority populations with COVID-19.
- COVID-19 disproportionately affects minority groups, necessitating research into effective treatments within these demographics.
Purpose of the Study:
- To evaluate the effectiveness of remdesivir in hospitalized COVID-19 patients from a predominantly Black and LatinX population.
- To identify factors associated with treatment outcomes in this demographic.
Main Methods:
- Retrospective cohort study of 206 adult COVID-19 patients treated with remdesivir.
- Data collected from May 2020 to April 2021 at an urban hospital in Newark, NJ.
- Outcomes assessed included 28-day mortality and clinical improvement using the WHO Ordinal Scale.
Main Results:
- Overall 28-day mortality was 11%.
- 81% of patients with baseline WHO status ≥4 recovered by day 14.
- Higher mortality was observed in older patients, those with diabetes, severe illness (WHO status ≥4), and those receiving tociluzimab or convalescent plasma.
Conclusions:
- Remdesivir demonstrated effectiveness in treating COVID-19 patients within this predominantly minority cohort.
- Traditional risk factors like advanced age and comorbidities significantly correlated with adverse clinical outcomes and mortality.
Objective:
Data on treatment outcomes among minority populations treated with remdesivir are limited. We sought to evaluate outcomes among patients hospitalized with COVID-19 and treated with remdesivir among a predominantly Black and LatinX population.
Methods:
This was a retrospective cohort study of adult patients hospitalized with COVID-19 and treated with remdesivir at an urban hospital in Newark, NJ, between May 1, 2020, and April 30, 2021, prior to widespread COVID-19 vaccination uptake. We describe 28-day mortality by demographic, socio-economic, and clinical factors, including clinical status by World Health Organization's (WHO) 8-point Ordinal Scale for Clinical Improvement.
Results:
A total of 206 patients met study inclusion criteria (52% were male, 41% non-Hispanic Black and 42% Hispanic). Overall mortality at 28 days was 11%. Eighty-one percent of patients with baseline WHO status of 4 or greater recovered by day 14. Mortality was higher among those who were older (p = 0.01), those with underlying diabetes mellitus (p = 0.047), those with more severe illness on admission by WHO Ordinal Scale (WHO status ≥ 4), and those on concomitant tociluzimab or convalescent plasma use.
Conclusions:
We found that remdesivir was effective in treating most COVID-19 patients in our study. Traditional risk factors, such as advanced age and underlying co-morbidities, were associated with worse clinical outcomes and deaths.
More Related Videos
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Related Concept Videos
01:51Vaccinations
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: